The Food and Drug Administration on Tuesday published a list of more than 200 brand name drugs without generic alternatives on the market. While the list leaves many drugmakers susceptible to more generic competition, Valeant Pharmaceuticals is poised to be hit the hardest, according to Investopedia.
Here are four things to know.
1. Wells Fargo analyst David Maris identified Valeant as the "one of the biggest potential victims" of the FDA's newest initiative to lower drug prices, according to a research note first cited by CNBC.
"[O]ur review shows no company in our coverage universe is more exposed to this new FDA effort than Valeant," Mr. Maris wrote.
2. Valeant products featured on the FDA's list include the eye drug Lotemax and Wilson's disease treatments Syprine and Cuprimine.
3. The listed drugs accounted for $713 million of Valeant's $9.67 billion revenue in 2016, according to Mr. Maris' estimates based on data from IMS Health.
4. Mr. Maris believes other companies will likely develop generic versions of these medications in the near future.
More articles on supply chain:
VA owes devicemakers $15M in late payments
GOP congressman loses $17M on pharma investment: 4 things to know
2 former Ariad Pharma execs charged with insider trading